CDSCO

The proposed amendments seek to strengthen accountability in drug manufacturing by requiring qualified personnel for batch release and maintaining prescribed records

Updated On: 03 Nov 2026 | 8:28 PM IST

Pharma executives seek clarity on export applicability of CDSCO's batch-wise solvent clearance rules, warning that approval delays could disrupt supplies, particularly in rural markets

Updated On: 03 Nov 2026 | 6:54 PM IST

Drug regulator CDSCO has mandated digital clearance for every batch of high-risk pharmaceutical solvents, prompting industry concerns over delays and potential supply disruptions

Updated On: 02 Nov 2026 | 10:38 PM IST

The regulator found that the product was being promoted online as a treatment for dissolving fat cells and reducing their size

Updated On: 02 Nov 2026 | 12:11 PM IST

Indian drug regulators ordered Sun Pharma to halt eye-care drug production at its Assam plant over quality lapses, following the recall of 332 batches of ophthalmic products.

Updated On: 30 Oct 2026 | 3:48 PM IST

The move is expected to reduce export approval timelines for biologics manufacturers using different brand names in overseas markets, provided the products are already approved in India

Updated On: 15 Oct 2026 | 7:18 PM IST

The Drugs Consultative Committee has sought a detailed proposal from Rajasthan amid concerns that machinery from closed pharma units could be used to make spurious drugs

Updated On: 02 Oct 2026 | 7:23 PM IST

The Drugs Consultative Committee has sought the DGHS opinion and data on Merbromin's manufacture and use before deciding on its continued inclusion under Schedule K

Updated On: 01 Oct 2026 | 8:47 PM IST

Drug regulator asks healthcare professionals and pharmacists to discourage indiscriminate use of NSAIDs and antibiotics, citing risks of kidney damage and CKD

Updated On: 22 Sep 2026 | 8:47 PM IST

Drug regulator proposes prominent age warning and pictorial label on cough syrups; the move comes after continued concerns over use of such medicines in very young children

Updated On: 19 Sep 2026 | 10:37 AM IST

DCGI Rajeev Raghuvanshi says the panel includes AI experts and will discuss how AI used in drug discovery should be evaluated, approved and regulated

Updated On: 18 Sep 2026 | 7:14 PM IST

Delhi authorities seized suspect Abhayrab vials from an unlicensed flat; samples failed potency tests and differed from genuine stock, prompting a regulatory alert

Updated On: 07 Sep 2026 | 4:27 PM IST

CDSCO expert panel grants waiver for 920 mg Ocrelizumab, subject to Roche conducting a Phase 4 clinical trial in the Indian population for proposed indications

Updated On: 04 Sep 2026 | 5:56 PM IST

Move follows expert concerns over potential misuse and intoxication; retailers will have to maintain detailed sales records for the four CNS medicines under Schedule H1

Updated On: 21 Aug 2026 | 9:52 PM IST

The consultations, scheduled for August 28, follow new ICMR guidelines proposing that a single Ethics Committee review all participating sites in multicentre research

Updated On: 10 Aug 2026 | 7:36 PM IST

The disease-modifying therapy for early Alzheimer's disease will cost ₹21,682 per vial, with treatment expenses varying according to patients' weight and dosage

Updated On: 04 Aug 2026 | 11:49 AM IST

The court sought replies from the Centre, ICMR and CDSCO on a PIL seeking disclosure of adverse event data and raising concerns over the HPV vaccination programme

Updated On: 22 Jul 2026 | 7:47 PM IST

The drugmaker will market Poviztra for treating MASH after CDSCO approved the new indication for innovator semaglutide, expanding the medicine's approved uses in India

Updated On: 20 Jul 2026 | 8:38 PM IST

The approval makes Wegovy the first GLP-1 therapy cleared in India for treating adults with non-cirrhotic MASH and moderate-to-advanced liver fibrosis

Updated On: 17 Jul 2026 | 5:40 PM IST

Novo Nordisk India on Friday said it has received approval from the Central Drugs Standard Control Organisation for indication of its Wegovy injection for the treatment of fatty liver disease in India. The Central Drugs Standard Control Organisation (CDSCO) has approved a new indication for Wegovy (semaglutide injection 2.4 mg), Novo Nordisk India said in a statement. It makes Wegovy the first and only GLP-1 RA to be approved both globally and in India for the treatment of noncirrhotic Metabolic Dysfunction Associated Steatohepatitis (MASH) in adults with moderate to advanced liver fibrosis along with a reduced calorie diet and increased physical activity, it added. MASH is a liver disease that develops due to excess fat buildup in the liver, causing chronic inflammation and liver damage. Novo Nordisk India MD Vikrant Shrotriya said the burden of MASH continues to rise in India, but treatment options are still severely limited. People with MASH face a higher risk of serious liver .

Updated On: 17 Jul 2026 | 2:59 PM IST